The stock of Foundation Medicine Inc (NASDAQ:FMI) is a huge mover today! About 277,397 shares traded hands or 79.80% up from the average. Foundation Medicine Inc (NASDAQ:FMI) has risen 29.28% since April 27, 2016 and is uptrending. It has outperformed by 24.06% the S&P500.
The move comes after 7 months negative chart setup for the $702.48M company. It was reported on Nov, 30 by Barchart.com. We have $18.75 PT which if reached, will make NASDAQ:FMI worth $63.22 million less.
Analysts await Foundation Medicine Inc (NASDAQ:FMI) to report earnings on February, 28. They expect $-1.00 EPS, down 81.82% or $0.45 from last year’s $-0.55 per share. After $-0.90 actual EPS reported by Foundation Medicine Inc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.
Foundation Medicine Inc (NASDAQ:FMI) Ratings Coverage
Out of 8 analysts covering Foundation Medicine (NASDAQ:FMI), 0 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 0 are positive. Foundation Medicine has been the topic of 10 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by BTIG Research given on Wednesday, November 4. On Thursday, July 30 the stock rating was downgraded by JMP Securities to “Market Perform”. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, September 16. The firm earned “Neutral” rating on Wednesday, September 21 by UBS. The rating was downgraded by Benchmark on Thursday, November 3 to “Hold”. The company was initiated on Monday, September 14 by BTIG Research.
According to Zacks Investment Research, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.67 in 2016 Q2. Its down 0.10, from 1.77 in 2016Q1. The ratio fall, as 10 funds sold all Foundation Medicine Inc shares owned while 16 reduced positions. 4 funds bought stakes while 42 increased positions. They now own 10.32 million shares or 3.75% less from 10.73 million shares in 2016Q1.
Geode Mngmt Llc, a Massachusetts-based fund reported 102,158 shares. Bessemer Gp Inc holds 0% or 6,725 shares in its portfolio. Winfield Associates last reported 800 shares in the company. The Delaware-based Blackrock Advsr Ltd Com has invested 0% in Foundation Medicine Inc (NASDAQ:FMI). Goldman Sachs Group Incorporated Inc holds 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI) for 21,385 shares. Credit Suisse Ag reported 21,493 shares or 0% of all its holdings. Whittier Trust Com holds 0.03% or 39,835 shares in its portfolio. Bancorp Of Montreal Can has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Prentiss Smith And Commerce accumulated 1,000 shares or 0.01% of the stock. The California-based Blackrock Fund Advsrs has invested 0% in Foundation Medicine Inc (NASDAQ:FMI). Millennium Mngmt Ltd Com has invested 0.01% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Chevy Chase Tru Inc has 729,310 shares for 0.08% of their US portfolio. Citigroup has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 122,264 shares or 0.03% of the stock. Dekabank Deutsche Girozentrale has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI).
Another recent and important Foundation Medicine Inc (NASDAQ:FMI) news was published by Businesswire.com which published an article titled: “Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products” on August 22, 2016.
FMI Company Profile
Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. The Company’s products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The Company’s flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.